Development of a clinical-grade ultrasensitive droplet digital PCR test for monitoring of relevant ESR1 variants by liquid biopsy
Breast cancer is the second most prevalent cancer-type globally. The current standard of care for hormone receptor-positive (HR+), human epidermal growth factor 2-negative (HER2-) advanced breast cancer (ABC) is endocrine therapy (ET) plus cyclin-dependent kinase 4/6 inhibitor (CDK4/6i). Most ABC patients receiving ET...